Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Safety Study of ADS-5102 in PD Patients With LID

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed a current IRB/REB/IEC-approved informed consent form~* Completed all study visits in previous Adamas efficacy study or were ineligible for participation in previous Adamas studies due to having undergone prior deep brain stimulation.~* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria~* On a stable regimen of antiparkinson's medications at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily.~* History of peak dose dyskinesia that might benefit from specific dyskinesia treatment in the judgment of the subject and clinical investigator~Exclusion Criteria:~* Discontinued ADS-5102 in previous Adamas efficacy study due to intolerable or unacceptable AEs considered to be related to ADS-5102~* History of neurosurgical intervention related to Parkinson's disease, with the exception of deep brain stimulation~* History of seizures since completion of participation in previous Adamas studies or within 2 years~* History of stroke or TIA since completion of participation in previous Adamas studies or within 2 years~* History of cancer since completion of participation in previous Adamas studies or within 2 years, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer~* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening~* If female is pregnant or lactating~* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment.~* Treatment with an investigational drug (other than ADS-5102) or device within 30 days prior to screening~* Treatment with an investigational biologic within 6 months prior to screening~* Current or planned participation in another interventional clinical trial

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ADS-5102 (Type: EXPERIMENTAL): amantadine HCl extended release

Based on this trial design, predict the completion outcome and termination type (if applicable).